552511939	552511939	CD	B-NP	O
|	|	NN	I-NP	O
LWHMC	LWHMC	NN	I-NP	O
|	|	NN	I-NP	O
22360573	22360573	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
3205059	3205059	CD	B-NP	O
|	|	CC	I-NP	O
5/22/2007	5/22/2007	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
CHF	CHF	NNP	I-NP	I-protein
|	|	NNP	I-NP	O
|	|	NNP	I-NP	O
DIS	DIS	NNP	I-NP	O
|	|	NNP	I-NP	O
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
5/25/2007	5/25/2007	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Discharge	Discharge	NNP	B-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
1/26/2007	1/26/2007	CD	B-NP	O
******	******	SYM	I-NP	O
FINAL	FINAL	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
ORDERS	ORDERS	NN	I-NP	O
******	******	SYM	B-VP	O
DINNEN	DINNEN	NN	B-NP	O
,	,	,	O	O
MAURO	MAURO	NN	B-NP	O
062-21-98-5	062-21-98-5	CD	I-NP	O
Moinesmifontdence	Moinesmifontdence	NNP	I-NP	O
Room	Room	NNP	I-NP	O
:	:	:	O	O
Mayflecmac	Mayflecmac	NNP	B-NP	O
Ln	Ln	NNP	I-NP	O
,	,	,	O	O
A	A	DT	B-NP	O
Ver	Ver	NNP	I-NP	O
Ara	Ara	NNP	I-NP	O
,	,	,	O	O
Iowa	Iowa	NNP	B-NP	O
79073	79073	CD	I-NP	O
Service	Service	NNP	I-NP	O
:	:	:	O	O
MED	MED	NNP	B-NP	O
DISCHARGE	DISCHARGE	NNP	I-NP	O
PATIENT	PATIENT	NNP	I-NP	O
ON	ON	NNP	I-NP	O
:	:	:	O	O
11/17/07	11/17/07	CD	B-NP	O
AT	AT	NN	I-NP	O
02	02	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
PM	PM	NN	I-NP	O
CONTINGENT	CONTINGENT	NN	I-NP	O
UPON	UPON	NN	I-NP	O
Attending	Attend	VBG	B-VP	O
evaluation	evaluation	NN	B-NP	O
WILL	WILL	NNP	I-NP	O
D/C	D/C	NNP	I-NP	O
ORDER	ORDER	NNP	I-NP	O
BE	BE	NNP	I-NP	O
USED	USED	NNP	I-NP	O
AS	AS	NNP	I-NP	O
THE	THE	NNP	I-NP	O
D/C	D/C	NNP	I-NP	O
SUMMARY	SUMMARY	NNP	I-NP	O
:	:	:	O	O
YES	YES	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
IVRIN	IVRIN	NNP	B-NP	O
,	,	,	O	O
ROD	ROD	NNP	B-NP	O
IAN	IAN	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
CODE	CODE	NNP	I-NP	O
STATUS	STATUS	NNP	I-NP	O
:	:	:	O	O
Full	Full	JJ	B-NP	O
code	code	NN	I-NP	O
DISPOSITION	DISPOSITION	NN	I-NP	O
:	:	:	O	O
Home	Home	NN	B-NP	O
w	w	NN	I-NP	O
/	/	SYM	B-NP	O
services	service	NNS	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
ASA	ASA	NN	B-NP	O
81	81	CD	B-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
Alert	Alert	NNP	I-NP	O
overridden	overridden	JJ	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
7/11/07	7/11/07	CD	B-NP	O
by	by	IN	B-PP	O
TAPPER	TAPPER	NN	B-NP	B-protein
,	,	,	O	O
MARTY	MARTY	NN	B-NP	O
,	,	,	O	O
M.D.	M.D.	NN	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
ASA	ASA	NN	B-NP	O
PO	PO	NN	I-NP	O
81	81	CD	I-NP	O
MG	MG	NN	I-NP	O
QD	QD	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
297166260	297166260	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
Pt	Pt	NN	I-NP	O
.	.	.	O	O

has	have	VBZ	O	O
a	a	DT	B-NP	O
PROBABLE	PROBABLE	NN	I-NP	O
allergy	allergy	NN	I-NP	O
to	to	TO	B-VP	O
SALSALATE	SALSALATE	VB	I-VP	O
;	;	:	O	O
reaction	reaction	NN	B-NP	O
is	be	VBZ	B-VP	O
Unknown	Unknown	JJ	B-ADJP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
.	.	.	O	O

has	have	VBZ	O	O
a	a	DT	B-NP	O
PROBABLE	PROBABLE	NN	I-NP	O
allergy	allergy	NN	I-NP	O
to	to	TO	B-PP	O
CELECOXIB	CELECOXIB	NN	B-NP	B-protein
;	;	:	O	O
reaction	reaction	NN	B-NP	O
is	be	VBZ	B-VP	O
Unknown	Unknown	JJ	B-ADJP	O
.	.	.	O	O

Reason	Reason	NN	B-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
patient	patient	NN	B-NP	O
tolerates	tolerate	VBZ	B-VP	O
ATENOLOL	ATENOLOL	NN	B-NP	B-protein
50	50	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
DAILY	DAILY	NNP	I-NP	O
Starting	Starting	NNP	I-NP	O
Today	Today	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
4/25	4/25	CD	I-NP	O
-RRB-	-RRB-	HYPH	I-NP	O
HOLD	HOLD	NN	I-NP	B-protein
IF	IF	NN	I-NP	I-protein
:	:	:	O	O
SBP	SBP	NN	B-NP	B-protein
<	<	SYM	O	O
100	100	CD	B-NP	O
,	,	,	O	O
HR	HR	NN	B-NP	O
<	<	SYM	O	O
55	55	CD	B-NP	O
Override	Override	NNP	I-NP	O
Notice	Notice	NNP	I-NP	O
:	:	:	O	O
Override	Override	NNP	B-NP	O
added	add	VBD	B-VP	O
on	on	IN	B-PP	O
11/17/07	11/17/07	CD	B-NP	O
by	by	IN	B-PP	O
DORLAND	DORLAND	NNP	B-NP	O
,	,	,	O	O
KENNETH	KENNETH	NNP	B-NP	O
G.	G.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
TIAZAC	TIAZAC	NN	B-NP	O
PO	PO	NN	I-NP	O
OTHER	OTHER	NN	I-NP	O
QD	QD	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
683733662	683733662	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
ATENOLOL	ATENOLOL	NNP	B-NP	O
&	&	CC	I-NP	O
DILTIAZEM	DILTIAZEM	NNP	I-NP	O
HCL	HCL	NN	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
aware	aware	JJ	B-NP	O
Previous	Previous	JJ	I-NP	O
override	override	NN	I-NP	O
information	information	NN	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
11/17/07	11/17/07	CD	B-NP	O
by	by	IN	B-PP	O
KUCK	KUCK	NNP	B-NP	O
,	,	,	O	O
BILLIE	BILLIE	NNP	B-NP	O
A.	A.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
DILTIAZEM	DILTIAZEM	NN	B-NP	O
HCL	HCL	NN	I-NP	O
&	&	CC	I-NP	O
ATENOLOL	ATENOLOL	NN	I-NP	O
Reason	Reason	NN	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
home	home	NN	B-NP	O
med	me	VBD	B-VP	O
PLAVIX	PLAVIX	NN	B-NP	B-protein
-LRB-	-LRB-	HYPH	B-NP	O
CLOPIDOGREL	CLOPIDOGREL	NN	I-NP	B-protein
-RRB-	-RRB-	HYPH	B-NP	O
75	75	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
DAILY	DAILY	NN	I-NP	O
VITAMIN	VITAMIN	NN	I-NP	O
B12	B12	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
CYANOCOBALAMIN	CYANOCOBALAMIN	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
50	50	CD	I-NP	O
MCG	MCG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
Number	Number	NNP	I-NP	O
of	of	IN	B-PP	O
Doses	Doses	NNP	B-NP	O
Required	Required	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
approximate	approximate	JJ	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
:	:	:	O	O
5	5	CD	B-NP	O
CARDIZEM	CARDIZEM	NN	I-NP	O
CD	CD	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
DILTIAZEM	DILTIAZEM	NN	I-NP	O
CD	CD	NN	I-NP	O
-LRB-	-LRB-	HYPH	B-NP	O
24	24	CD	I-NP	O
HR	HR	NN	I-NP	O
CAPS	CAPS	NN	I-NP	O
-RRB-	-RRB-	SYM	B-VP	O
-RRB-	-RRB-	NN	B-NP	O
240	240	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
Avoid	Avoid	NNP	I-NP	O
grapefruit	grapefruit	NN	I-NP	O
unless	unless	IN	B-SBAR	O
MD	MD	NN	B-NP	B-DNA
instructs	instruct	NNS	I-NP	I-DNA
otherwise	otherwise	RB	B-ADVP	O
.	.	.	O	O

Alert	Alert	NNP	B-NP	O
overridden	overridden	JJ	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
11/17/07	11/17/07	CD	B-NP	O
by	by	IN	B-PP	O
:	:	:	O	O
POTENTIALLY	POTENTIALLY	NNP	B-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
ATENOLOL	ATENOLOL	NNP	B-NP	O
&	&	CC	I-NP	O
DILTIAZEM	DILTIAZEM	NNP	I-NP	O
HCL	HCL	NN	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
home	home	NN	B-NP	O
med	me	VBD	B-VP	O
LASIX	LASIX	NN	B-NP	B-protein
-LRB-	-LRB-	HYPH	B-NP	O
FUROSEMIDE	FUROSEMIDE	NN	I-NP	B-protein
-RRB-	-RRB-	HYPH	I-NP	I-protein
40	40	CD	I-NP	I-protein
MG	MG	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
DAILY	DAILY	NN	I-NP	I-protein
HOLD	HOLD	NN	I-NP	I-protein
IF	IF	NN	I-NP	I-protein
:	:	:	O	O
SBP	SBP	NN	B-NP	B-protein
<	<	SYM	O	O
100	100	CD	B-NP	O
Alert	Alert	NNP	I-NP	O
overridden	overridden	JJ	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
11/17/07	11/17/07	CD	B-NP	O
by	by	IN	B-PP	O
INNISS	INNISS	NNP	B-NP	O
,	,	,	O	O
BRICE	BRICE	NNP	B-NP	O
G.	G.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
LASIX	LASIX	NN	B-NP	O
PO	PO	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
549675542	549675542	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
Pt	Pt	NN	I-NP	O
.	.	.	O	O

has	have	VBZ	O	O
a	a	DT	B-NP	O
POSSIBLE	POSSIBLE	NN	I-NP	O
allergy	allergy	NN	I-NP	O
to	to	TO	B-PP	O
CELECOXIB	CELECOXIB	NN	B-NP	B-protein
;	;	:	O	O
reaction	reaction	NN	B-NP	O
is	be	VBZ	B-VP	O
Unknown	Unknown	JJ	B-ADJP	O
.	.	.	O	O

Reason	Reason	NN	B-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
home	home	NN	B-NP	O
med	me	VBD	B-VP	O
INSULIN	INSULIN	NNP	B-NP	B-protein
NPH	NPH	NNP	I-NP	O
HUMAN	HUMAN	NNP	I-NP	O
16	16	CD	I-NP	O
UNITS	UNITS	NNP	I-NP	O
SC	SC	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
Starting	Starting	NNP	I-NP	O
Today	Today	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
4/25	4/25	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Instructions	Instruction	NNPS	I-NP	O
:	:	:	O	O
take	take	VB	B-VP	O
in	in	RP	B-PRT	O
evening	evening	NN	B-NP	O
as	as	IN	B-SBAR	O
you	you	PRP	B-NP	O
always	always	RB	B-ADVP	O
have	have	VBP	B-VP	O
AVAPRO	AVAPRO	NN	B-NP	B-protein
-LRB-	-LRB-	NN	I-NP	I-protein
IRBESARTAN	IRBESARTAN	NN	I-NP	I-protein
-RRB-	-RRB-	HYPH	B-NP	I-protein
300	300	CD	I-NP	I-protein
MG	MG	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
DAILY	DAILY	NN	I-NP	I-protein
HOLD	HOLD	NN	I-NP	I-protein
IF	IF	NN	I-NP	I-protein
:	:	:	O	O
sbp	sbp	NN	B-NP	O
<	<	SYM	O	O
100	100	CD	B-NP	O
Alert	Alert	NNP	I-NP	O
overridden	overridden	JJ	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
7/11/07	7/11/07	CD	B-NP	O
by	by	IN	B-PP	O
RIPKA	RIPKA	NNP	B-NP	B-protein
,	,	,	O	O
BENITO	BENITO	NNP	B-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
POTASSIUM	POTASSIUM	NNP	B-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
&	&	CC	I-NP	O
IRBESARTAN	IRBESARTAN	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
patient	patient	NN	B-NP	O
tolerates	tolerate	VBZ	B-VP	O
Number	Number	NNP	B-NP	O
of	of	IN	B-PP	O
Doses	Doses	NNP	B-NP	O
Required	Required	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
approximate	approximate	JJ	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
:	:	:	O	O
5	5	CD	B-NP	O
IMDUR	IMDUR	NN	I-NP	O
ER	ER	NN	I-NP	B-protein
-LRB-	-LRB-	HYPH	B-NP	O
ISOSORBIDE	ISOSORBIDE	NN	I-NP	B-protein
MONONITRATE	MONONITRATE	NN	I-NP	I-protein
-LRB-	-LRB-	NN	I-NP	I-protein
SR	SR	NN	I-NP	I-protein
-RRB-	-RRB-	NN	I-NP	I-protein
-RRB-	-RRB-	HYPH	B-NP	O
300	300	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
DAILY	DAILY	NN	I-NP	O
HOLD	HOLD	NN	I-NP	O
IF	IF	NN	I-NP	O
:	:	:	O	O
SBP	SBP	NN	B-NP	B-protein
<	<	SYM	O	O
100	100	CD	B-NP	O
Food/Drug	Food/Drug	NN	I-NP	O
Interaction	Interaction	NN	I-NP	O
Instruction	Instruction	NN	I-NP	O
Give	Give	NN	I-NP	O
on	on	IN	B-PP	O
an	an	DT	B-NP	O
empty	empty	JJ	I-NP	O
stomach	stomach	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
give	give	VBP	B-VP	O
1hr	1hr	NN	B-NP	O
before	before	IN	B-SBAR	O
or	or	CC	O	O
2hr	2hr	NN	B-NP	O
after	after	IN	B-PP	O
food	food	NN	B-NP	B-protein
-RRB-	-RRB-	NN	I-NP	I-protein
METFORMIN	METFORMIN	NN	I-NP	I-protein
500	500	CD	I-NP	I-protein
MG	MG	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
TID	TID	NN	I-NP	I-protein
MICONAZOLE	MICONAZOLE	NN	I-NP	I-protein
NITRATE	NITRATE	NN	I-NP	I-protein
2	2	CD	B-NP	I-protein
%	%	NN	I-NP	I-protein
POWDER	POWDER	NN	I-NP	I-protein
TOPICAL	TOPICAL	NN	I-NP	I-protein
TP	TP	NN	I-NP	I-protein
BID	BID	NN	I-NP	I-protein
AVANDIA	AVANDIA	NN	I-NP	I-protein
-LRB-	-LRB-	NN	I-NP	I-protein
ROSIGLITAZONE	ROSIGLITAZONE	NN	I-NP	I-protein
-RRB-	-RRB-	NN	I-NP	I-protein
8	8	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
DAILY	DAILY	NNP	I-NP	I-protein
ZOCOR	ZOCOR	NNP	I-NP	I-protein
-LRB-	-LRB-	NNP	I-NP	I-protein
SIMVASTATIN	SIMVASTATIN	NNP	I-NP	I-protein
-RRB-	-RRB-	NNP	I-NP	I-protein
40	40	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
BEDTIME	BEDTIME	NNP	I-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
Avoid	Avoid	NNP	I-NP	O
grapefruit	grapefruit	NN	I-NP	O
unless	unless	IN	B-SBAR	O
MD	MD	NN	B-NP	B-DNA
instructs	instruct	NNS	I-NP	I-DNA
otherwise	otherwise	RB	B-ADVP	O
.	.	.	O	O

DIET	DIET	NN	B-NP	O
:	:	:	O	O
Fluid	Fluid	NN	B-NP	O
restriction	restriction	NN	I-NP	O
DIET	DIET	NN	I-NP	O
:	:	:	O	O
House	House	NNP	B-NP	O
/	/	SYM	B-NP	O
Low	Low	JJ	I-NP	O
chol/low	chol/low	NN	I-NP	O
sat	sat	NN	I-NP	O
.	.	.	O	O

fat	fat	JJ	B-NP	O
DIET	DIET	NN	I-NP	O
:	:	:	O	O
2	2	CD	B-NP	O
gram	gram	NN	I-NP	O
Sodium	Sodium	NN	I-NP	O
ACTIVITY	ACTIVITY	NN	I-NP	O
:	:	:	O	O
Walking	Walk	VBG	B-VP	O
as	as	IN	B-SBAR	O
tolerated	tolerate	VBN	B-NP	O
FOLLOW	FOLLOW	NNP	I-NP	O
UP	UP	NNP	I-NP	O
APPOINTMENT	APPOINTMENT	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
S	S	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
:	:	:	O	O
Dr.	Dr.	NNP	B-NP	O
Bolster	Bolster	NNP	I-NP	O
-	-	HYPH	B-NP	O
please	please	NN	I-NP	O
call	call	NN	I-NP	O
for	for	IN	B-PP	O
appt	appt	NN	B-NP	O
in	in	IN	B-PP	O
1	1	CD	B-NP	O
month	month	NN	I-NP	O
,	,	,	O	O
PCP	PCP	NN	B-NP	O
please	please	NN	I-NP	O
call	call	NN	I-NP	O
for	for	IN	B-PP	O
appt	appt	NN	B-NP	O
in	in	IN	B-PP	O
1-2	1-2	CD	B-NP	O
weeks	week	NNS	I-NP	O
,	,	,	O	O
ALLERGY	ALLERGY	NN	B-NP	O
:	:	:	O	O
Penicillins	Penicillins	NNP	B-NP	O
,	,	,	O	O
ACE	ACE	NNP	B-NP	O
Inhibitor	Inhibitor	NNP	I-NP	O
,	,	,	O	O
Erythromycins	Erythromycins	NNP	B-NP	O
,	,	,	O	O
GABAPENTIN	GABAPENTIN	NN	B-NP	B-protein
,	,	,	O	O
TETANUS	TETANUS	NN	B-NP	O
,	,	,	O	O
SALSALATE	SALSALATE	NNP	B-NP	O
,	,	,	O	O
CELECOXIB	CELECOXIB	NNP	B-NP	O
,	,	,	O	O
AMIDE	AMIDE	NNP	B-NP	O
ANESTHETICS	ANESTHETICS	NNP	I-NP	O
ADMIT	ADMIT	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
:	:	:	O	O
CHF	CHF	NN	B-NP	O
PRINCIPAL	PRINCIPAL	JJ	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
;	;	:	O	O
Responsible	Responsible	JJ	B-ADJP	O
After	After	IN	B-PP	O
Study	Study	NNP	B-NP	O
for	for	IN	B-PP	O
Causing	Causing	NNP	B-NP	O
Admission	Admission	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
CHF	CHF	NNP	I-NP	O
OTHER	OTHER	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
;	;	:	O	O
Conditions	Condition	NNS	B-NP	O
,	,	,	O	O
Infections	Infection	NNS	B-NP	O
,	,	,	O	O
Complications	Complication	NNS	B-NP	O
,	,	,	O	O
affecting	affect	VBG	B-VP	O
Treatment/Stay	Treatment/Stay	NNP	B-NP	O
HTN	HTN	NN	I-NP	O
,	,	,	O	O
Diabetes	Diabetes	NNP	B-NP	O
,	,	,	O	O
OSA	OSA	NNP	B-NP	O
OPERATIONS	OPERATIONS	NNPS	I-NP	O
AND	AND	CC	I-NP	O
PROCEDURES	PROCEDURES	NNPS	I-NP	O
:	:	:	O	O
OTHER	OTHER	NN	B-NP	O
TREATMENTS/PROCEDURES	TREATMENTS/PROCEDURES	VBZ	B-VP	O
-LRB-	-LRB-	NNP	B-NP	O
NOT	NOT	NNP	I-NP	O
IN	IN	NNP	I-NP	O
O.R.	O.R.	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
diuresis	diuresis	NN	I-NP	O
with	with	IN	B-PP	O
IV	IV	CD	B-NP	O
lasix	lasix	CD	I-NP	O
echocardiogram	echocardiogram	NN	I-NP	O
BRIEF	BRIEF	NN	I-NP	O
RESUME	RESUME	NN	I-NP	O
OF	OF	IN	B-PP	O
HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
:	:	:	O	O
CC	CC	NN	B-NP	O
:	:	:	O	O
shortness	shortness	NN	B-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
HPI	HPI	NN	I-NP	O
:	:	:	O	O
73	73	CD	B-NP	O
yo	yo	NN	I-NP	O
f	f	NN	I-NP	O
w/CAD	w/CAD	NN	I-NP	O
and	and	CC	O	O
CHF-lmtd	CHF-lmtd	JJ	B-NP	O
baseline	baseline	NN	I-NP	O
ex	ex	NN	I-NP	O
capacity	capacity	NN	I-NP	O
.	.	.	O	O

Increasine	Increasine	NNP	B-NP	O
DOE	DOE	NNP	I-NP	O
and	and	CC	O	O
difficulty	difficulty	NN	B-NP	O
performing	perform	VBG	B-VP	O
ADLs	ADL	NNS	B-NP	B-protein
since	since	IN	B-SBAR	O
9/5	9/5	CD	B-NP	O
Stable	Stable	JJ	I-NP	O
orthopnea	orthopnea	NN	I-NP	O
,	,	,	O	O
new	new	JJ	B-NP	O
PND	PND	NN	I-NP	O
.	.	.	O	O

Also	Also	RB	B-ADVP	O
p/w	p/w	VB	B-VP	O
some	some	DT	B-NP	O
throat	throat	NN	I-NP	O
fullness	fullness	NN	I-NP	O
and	and	CC	O	O
chst	chst	NN	B-NP	O
tightness	tightness	NN	I-NP	O
on	on	IN	B-PP	O
L-not	L-not	NN	B-NP	B-protein
anginal	anginal	JJ	I-NP	I-protein
equivalent	equivalent	NN	I-NP	I-protein
.	.	.	O	O
.	.	.	O	O

at	at	IN	B-PP	O
rest	rest	NN	B-NP	O
,	,	,	O	O
last	last	JJ	B-NP	O
2	2	CD	I-NP	O
hours	hour	NNS	I-NP	O
,	,	,	O	O
relief	relief	NN	B-NP	O
20min	20min	NN	I-NP	O
p	p	NN	I-NP	O
NTG	NTG	NN	I-NP	O
.	.	.	O	O

Has	Has	NNP	B-NP	O
missed	miss	VBD	B-VP	O
2	2	CD	B-NP	O
doses	dose	NNS	I-NP	O
of	of	IN	B-PP	O
lasix	lasix	NN	B-NP	O
but	but	CC	O	O
is	be	VBZ	B-VP	O
otherwise	otherwise	RB	B-ADJP	O
compliant	compliant	JJ	I-ADJP	O
.	.	.	O	O

Last	Last	JJ	B-NP	O
ECHO	ECHO	NN	I-NP	O
2003-mild	2003-mild	JJ	I-NP	O
LAE	LAE	NN	I-NP	O
,	,	,	O	O
1-2	1-2	NN	B-NP	O
+	+	SYM	B-NP	O
MR	MR	NN	I-NP	B-protein
,	,	,	O	O
mild-mod	mild-mod	JJ	B-NP	O
inf	inf	NN	I-NP	O
HK	HK	NN	I-NP	O
.	.	.	O	O

Last	Last	JJ	B-NP	O
cath	cath	NN	I-NP	O
2005-LAD	2005-LAD	JJ	I-NP	O
40	40	CD	I-NP	O
%	%	NN	I-NP	O
prox	prox	NN	I-NP	O
and	and	CC	O	O
30	30	CD	B-NP	O
%	%	NN	I-NP	O
mid	mid	NN	I-NP	O
,	,	,	O	O
RCA	RCA	NN	B-NP	O
100	100	CD	B-NP	O
%	%	NN	I-NP	O
mid-old	mid-old	JJ	B-ADJP	O
since	since	IN	B-PP	O
2001	2001	CD	B-NP	O
,	,	,	O	O
LAD	LAD	NN	B-NP	O
PDA	PDA	NN	I-NP	O
collaterals	collateral	NNS	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
ED	ED	NN	B-NP	O
97	97	CD	B-NP	O
%	%	NN	I-NP	O
RA	RA	NN	I-NP	O
.	.	.	O	O

PMH	PMH	NN	B-NP	O
:	:	:	O	O
HTN	HTN	NN	B-NP	B-protein
,	,	,	O	O
CHF	CHF	NN	B-NP	B-protein
,	,	,	O	O
hyperthyroidism	hyperthyroidism	NN	B-NP	O
,	,	,	O	O
h/o	h/o	NN	B-NP	O
monoclonal	monoclonal	JJ	I-NP	O
gammopathy	gammopathy	NN	I-NP	O
,	,	,	O	O
CAD	CAD	NN	B-NP	O
s/p	s/p	NN	I-NP	O
cx	cx	NN	I-NP	O
stent	stent	NN	I-NP	O
2001	2001	CD	I-NP	O
,	,	,	O	O
OSA	OSA	NN	B-NP	O
on	on	IN	B-PP	O
CPAP	CPAP	NN	B-NP	B-protein
,	,	,	O	O
DM	DM	NN	B-NP	O
,	,	,	O	O
nephrolithiasis	nephrolithiasis	NN	B-NP	O
,	,	,	O	O
CKD	CKD	NN	B-NP	B-protein
1.3	1.3	CD	I-NP	I-protein
,	,	,	O	O
spinal	spinal	JJ	B-NP	O
stneosis	stneosis	NN	I-NP	O
ALL	ALL	NN	I-NP	O
:	:	:	O	O
PCN	PCN	NN	B-NP	B-protein
,	,	,	O	O
ACE	ACE	NN	B-NP	O
,	,	,	O	O
emycin	emycin	NN	B-NP	O
,	,	,	O	O
neurotin	neurotin	NN	B-NP	B-protein
,	,	,	O	O
tetanus	tetanus	NN	B-NP	O
,	,	,	O	O
salsalate	salsalate	NN	B-NP	O
,	,	,	O	O
celebrex	celebrex	NN	B-NP	O
,	,	,	O	O
amide	amide	NN	B-NP	O
anesthetics	anesthetic	NNS	I-NP	O
HOME	HOME	NNP	B-NP	O
MEDS	MEDS	NNP	I-NP	O
:	:	:	O	O
asa	asa	NN	B-NP	O
81	81	CD	I-NP	O
,	,	,	O	O
nph	nph	NN	B-NP	O
16	16	CD	I-NP	O
,	,	,	O	O
imdur	imdur	NN	B-NP	O
300	300	CD	I-NP	O
,	,	,	O	O
cardizem	cardizem	NN	B-NP	O
240	240	CD	I-NP	O
,	,	,	O	O
plvix	plvix	NN	B-NP	B-protein
75	75	CD	I-NP	I-protein
,	,	,	O	O
atenolol	atenolol	NN	B-NP	O
75	75	CD	I-NP	O
,	,	,	O	O
lasix	lasix	CD	B-NP	O
40	40	CD	I-NP	O
,	,	,	O	O
lipitor	lipitor	NN	B-NP	O
20	20	CD	I-NP	O
,	,	,	O	O
metformin	metformin	NN	B-NP	O
500	500	CD	I-NP	O
tid	tid	NN	I-NP	O
,	,	,	O	O
avandia	avandia	NN	B-NP	B-protein
8	8	CD	I-NP	I-protein
,	,	,	O	O
avapro	avapro	NN	B-NP	O
300	300	CD	I-NP	O
,	,	,	O	O
B12	B12	NN	B-NP	B-protein
**********************	**********************	SYM	I-NP	O
ADMIT	ADMIT	NN	I-NP	O
STATUS	STATUS	NNS	I-NP	O
:	:	:	O	O
97	97	CD	B-NP	O
%	%	NN	I-NP	O
RA	RA	NN	I-NP	O
,	,	,	O	O
140.60	140.60	CD	B-NP	O
HR	HR	NN	I-NP	O
49	49	CD	B-NP	O
oriented	orient	VBN	B-VP	O
,	,	,	O	O
abd	abd	NN	B-NP	O
benign	benign	JJ	I-NP	O
,	,	,	O	O
ctab	ctab	NN	B-NP	O
,	,	,	O	O
2/6	2/6	CD	B-NP	O
sys	sy	NNS	I-NP	O
m	m	NN	I-NP	O
at	at	IN	B-PP	O
apex	apex	NN	B-NP	O
,	,	,	O	O
chronic	chronic	JJ	B-NP	O
LE	LE	NN	I-NP	O
edema	edema	NN	I-NP	O
************************	************************	SYM	B-NP	O
STUDIES	STUDIES	NN	I-NP	O
:	:	:	O	O
CXR	CXR	NN	B-NP	B-protein
cardiomegaly	cardiomegaly	RB	B-NP	O
stable	stable	JJ	I-NP	O
EKG	EKG	NN	I-NP	O
1st	1st	CD	I-NP	O
AV	AV	NN	I-NP	O
block	block	NN	I-NP	O
,	,	,	O	O
old	old	JJ	B-NP	O
inf	inf	NN	I-NP	O
qs	q	NNS	I-NP	O
ECHO	ECHO	NN	I-NP	O
7/18	7/18	CD	I-NP	O
,	,	,	O	O
MR	MR	NN	B-NP	B-protein
,	,	,	O	O
mild-mon	mild-mon	JJ	B-NP	B-protein
inf	inf	NN	I-NP	I-protein
HK	HK	NN	I-NP	I-protein
,	,	,	O	O
EF	EF	NN	B-NP	O
55	55	CD	B-NP	O
%	%	NN	I-NP	O
,	,	,	O	O
unchanged	unchanged	JJ	B-ADJP	O
from	from	IN	B-PP	O
prior	prior	JJ	B-NP	O
*********************	*********************	SYM	I-NP	O
HOSPITAL	HOSPITAL	JJ	I-NP	O
COURSE	COURSE	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

DYSPNEA	DYSPNEA	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
presented	present	VBD	B-VP	O
with	with	IN	B-PP	O
increased	increase	VBN	B-NP	O
dyspnea	dyspnea	NN	I-NP	O
on	on	IN	B-PP	O
exertion	exertion	NN	B-NP	O
,	,	,	O	O
likely	likely	RB	B-ADJP	O
secondary	secondary	JJ	I-ADJP	O
to	to	TO	B-PP	O
CHF	CHF	NN	B-NP	B-protein
with	with	IN	B-PP	O
preserved	preserve	VBN	B-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
EKG	EKG	NN	I-NP	B-protein
was	be	VBD	B-VP	O
without	without	IN	B-PP	O
changes	change	NNS	B-NP	O
from	from	IN	B-PP	O
prior	prior	JJ	B-ADJP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
cardiac	cardiac	JJ	I-NP	B-protein
enzymes	enzyme	NNS	I-NP	I-protein
were	be	VBD	B-VP	O
cycled	cycle	VBN	I-VP	O
and	and	CC	O	O
negative	negative	JJ	B-NP	O
x3	x3	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
40mg	40mg	NN	B-NP	O
IV	IV	CD	I-NP	O
lasix	lasix	NN	I-NP	O
with	with	IN	B-PP	O
approx	approx	NN	B-NP	O
2L	2L	NN	I-NP	O
diuresis	diuresis	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
weight	weight	NN	I-NP	O
at	at	IN	B-PP	O
discharge	discharge	NN	B-NP	O
was	be	VBD	B-VP	O
127.3	127.3	CD	B-NP	O
kg	kg	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
admission	admission	NN	I-NP	O
weight	weight	NN	I-NP	O
was	be	VBD	B-VP	O
131.5	131.5	CD	B-NP	O
kg	kg	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
an	an	DT	B-NP	O
ECHO	ECHO	NN	I-NP	B-protein
which	which	WDT	B-NP	O
showed	show	VBD	B-VP	O
an	an	DT	B-NP	O
EF	EF	NN	I-NP	B-protein
of	of	IN	B-PP	O
55	55	CD	B-NP	O
%	%	NN	I-NP	O
and	and	CC	I-NP	O
1-2	1-2	NN	I-NP	O
+	+	SYM	O	O
MR	MR	NN	B-NP	B-protein
with	with	IN	B-PP	O
slightly	slightly	RB	B-NP	O
elevated	elevated	JJ	I-NP	O
PA	PA	NN	I-NP	O
pressure	pressure	NN	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
was	be	VBD	B-VP	O
unchanged	unchanged	JJ	B-ADJP	O
from	from	IN	B-PP	O
her	her	PRP$	B-NP	O
previous	previous	JJ	I-NP	O
ECHO	ECHO	NN	I-NP	O
in	in	IN	B-PP	O
2003	2003	CD	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
CXR	CXR	NN	I-NP	B-protein
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
show	show	VB	I-VP	O
any	any	DT	B-NP	O
acute	acute	JJ	I-NP	O
process	process	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
DDimer	DDimer	NN	I-NP	O
of	of	IN	B-PP	O
2300	2300	CD	B-NP	O
.	.	.	O	O

LENIS	LENIS	NN	B-NP	B-protein
showed	show	VBD	B-VP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
a	a	DT	B-NP	O
DVT	DVT	NN	I-NP	B-DNA
and	and	CC	O	O
on	on	IN	B-PP	O
7/18	7/18	CD	B-NP	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
CT	CT	NN	I-NP	O
with	with	IN	B-PP	O
PE	PE	NN	B-NP	O
protocol	protocol	NN	I-NP	O
which	which	WDT	B-NP	O
showed	show	VBD	B-VP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
a	a	DT	B-NP	O
DVT	DVT	NN	I-NP	B-protein
or	or	CC	I-NP	O
PE	PE	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
mucomyst	mucomyst	NN	B-NP	O
for	for	IN	B-PP	O
this	this	DT	B-NP	O
for	for	IN	B-PP	O
renal	renal	JJ	B-NP	O
protection	protection	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
CPAP	CPAP	NN	I-NP	B-protein
for	for	IN	B-PP	O
OSA	OSA	NN	B-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

HTN	HTN	NN	B-NP	B-protein
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
avapro	avapro	NN	I-NP	O
and	and	CC	I-NP	O
Imdur	Imdur	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
diltiazem	diltiazem	NN	I-NP	O
and	and	CC	I-NP	O
atenolol	atenolol	NN	I-NP	O
doses	dose	NNS	I-NP	O
were	be	VBD	B-VP	O
decreased	decrease	VBN	I-VP	O
as	as	IN	B-SBAR	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
having	have	VBG	I-VP	O
bradycardia	bradycardia	NN	B-NP	O
with	with	IN	B-PP	O
rates	rate	NNS	B-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
40s	40	NNS	I-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
first	first	JJ	I-NP	O
day	day	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
hospital	hospital	NN	I-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

CAD	CAD	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
imdur	imdur	NN	I-NP	O
,	,	,	O	O
beta	beta	NN	B-NP	O
blocker	blocker	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
aspirin	aspirin	NN	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
plavix	plavix	NN	I-NP	O
was	be	VBD	B-VP	O
held	hold	VBN	I-VP	O
as	as	IN	B-SBAR	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
holding	hold	VBG	I-VP	O
this	this	DT	B-NP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
for	for	IN	B-PP	O
upcoming	upcome	VBG	B-VP	O
cataract	cataract	NN	B-NP	O
surgery	surgery	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
last	last	JJ	I-NP	O
stent	stent	NN	I-NP	O
was	be	VBD	B-VP	O
2001	2001	CD	B-NP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
permission	permission	NN	B-NP	O
by	by	IN	B-PP	O
her	her	PRP$	B-NP	O
outpatient	outpatient	NN	I-NP	O
cardiologist	cardiologist	NN	I-NP	O
to	to	TO	B-VP	O
hold	hold	VB	I-VP	O
this	this	DT	B-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

DM	DM	NN	B-NP	O
:	:	:	O	O
Her	Her	PRP$	B-NP	O
avandia	avandia	NN	I-NP	O
and	and	CC	I-NP	O
metformin	metformin	NN	I-NP	O
were	be	VBD	B-VP	O
held	hold	VBN	I-VP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
NPH	NPH	NN	I-NP	B-protein
and	and	CC	O	O
a	a	DT	B-NP	O
sliding	slide	VBG	I-NP	O
scale	scale	NN	I-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

RENAL	RENAL	NN	B-NP	O
:	:	:	O	O
Her	Her	PRP$	B-NP	O
Cr	Cr	NN	I-NP	O
.	.	.	O	O

was	be	VBD	B-VP	O
1.4	1.4	CD	B-NP	O
at	at	IN	B-PP	O
admission	admission	NN	B-NP	O
and	and	CC	O	O
improved	improve	VBN	B-VP	O
to	to	TO	B-PP	O
1.1	1.1	CD	B-NP	O
with	with	IN	B-PP	O
diuresis	diuresis	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
mucomyst	mucomyst	NN	B-NP	O
for	for	IN	B-PP	O
renal	renal	JJ	B-NP	O
protection	protection	NN	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

FEN	FEN	NN	B-NP	O
:	:	:	O	O
She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
maintained	maintain	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
2L	2L	NN	I-NP	O
fluid	fluid	NN	I-NP	O
restriction	restriction	NN	I-NP	O
and	and	CC	O	O
2g	2g	NN	B-NP	O
Na	Na	NN	I-NP	O
restriction	restriction	NN	I-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

PPX	PPX	NN	B-NP	B-protein
:	:	:	O	O
heparin	heparin	NN	B-NP	O
tid	tid	NN	I-NP	O
ADDITIONAL	ADDITIONAL	NN	I-NP	O
COMMENTS	COMMENTS	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Call	Call	VB	B-VP	O
your	your	PRP$	B-NP	O
doctor	doctor	NN	I-NP	O
if	if	IN	B-SBAR	O
you	you	PRP	B-NP	O
have	have	VBP	B-VP	O
any	any	DT	B-NP	O
more	more	JJR	I-NP	O
shortness	shortness	NN	I-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
or	or	CC	I-NP	O
difficulty	difficulty	NN	I-NP	O
doing	do	VBG	B-VP	O
your	your	PRP$	B-NP	O
daily	daily	JJ	I-NP	O
activities	activity	NNS	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Resume	Resume	VB	B-VP	O
your	your	PRP$	B-NP	O
usual	usual	JJ	I-NP	O
home	home	NN	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
lasix	lasix	NN	B-NP	O
,	,	,	O	O
monitor	monitor	VB	B-VP	O
your	your	PRP$	B-NP	O
weight	weight	NN	I-NP	O
daily	daily	RB	B-ADVP	O
and	and	CC	O	O
call	call	VB	B-VP	O
your	your	PRP$	B-NP	O
doctor	doctor	NN	I-NP	O
if	if	IN	B-SBAR	O
your	your	PRP$	B-NP	O
weight	weight	NN	I-NP	O
is	be	VBZ	B-VP	O
increasing	increase	VBG	I-VP	O
.	.	.	O	O

Eat	Eat	VB	B-VP	O
a	a	DT	B-NP	O
diet	diet	NN	I-NP	O
low	low	JJ	B-ADJP	O
in	in	IN	B-PP	O
salt	salt	NN	B-NP	B-protein
-LRB-	-LRB-	NN	I-NP	I-protein
less	less	JJR	B-NP	O
than	than	IN	I-NP	O
2	2	CD	I-NP	O
grams	gram	NNS	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

We	We	PRP	B-NP	O
have	have	VBP	B-VP	O
decreased	decrease	VBN	I-VP	O
the	the	DT	B-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
your	your	PRP$	B-NP	O
atenolol	atenolol	NN	I-NP	O
to	to	TO	B-PP	O
50mg	50mg	CD	B-NP	O
daily	daily	JJ	I-NP	O
-LRB-	-LRB-	HYPH	I-NP	O
1	1	CD	I-NP	O
pill	pill	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Please	Please	VB	B-VP	O
have	have	VB	I-VP	O
your	your	PRP$	B-NP	O
PCP	PCP	NN	I-NP	O
Dr.	Dr.	NNP	I-NP	O
Nickless	Nickless	NNP	I-NP	O
check	check	VB	B-VP	O
your	your	PRP$	B-NP	O
creatinine	creatinine	NN	I-NP	O
on	on	IN	B-PP	O
Friday	Friday	NNP	B-NP	O
November	November	NNP	I-NP	O
This	This	NNP	I-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
arranged	arrange	VBN	I-VP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
office	office	NN	I-NP	O
will	will	MD	B-VP	O
contact	contact	VB	I-VP	O
you	you	PRP	B-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Please	Please	NNP	B-NP	O
call	call	NN	I-NP	O
Dr.	Dr.	NNP	I-NP	O
Lychwala	Lychwala	NNP	I-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
follow	follow	NN	I-NP	O
up	up	RP	B-PRT	O
appointment	appointment	NN	B-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
CONDITION	CONDITION	NN	I-NP	O
:	:	:	O	O
Stable	Stable	JJ	B-NP	O
TO	TO	NN	I-NP	O
DO/PLAN	DO/PLAN	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Please	Please	NN	B-NP	B-protein
follow	follow	VBP	B-VP	O
patient	patient	NN	B-NP	O
's	's	POS	B-NP	O
Cr	Cr	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
received	receive	VBD	B-VP	O
contrast	contrast	NN	B-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
CT.	CT.	NN	I-NP	B-protein
2	2	CD	I-NP	I-protein
.	.	.	O	O

Please	Please	VB	B-VP	O
adjust	adjust	JJ	B-NP	O
BP	BP	NN	I-NP	O
meds	med	NNS	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
atenolol	atenolol	NN	I-NP	O
dose	dose	NN	I-NP	O
was	be	VBD	B-VP	O
decreased	decrease	VBN	I-VP	O
because	because	IN	B-SBAR	O
her	her	PRP$	B-NP	O
heart	heart	NN	I-NP	O
rate	rate	NN	I-NP	O
was	be	VBD	B-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
40s	40	NNS	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Please	Please	VB	B-VP	O
evaluate	evaluate	VB	I-VP	O
her	her	PRP$	B-NP	O
anemia	anemia	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
Hct	Hct	NN	I-NP	B-protein
was	be	VBD	B-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
low	low	JJ	I-NP	O
30s	30	NNS	I-NP	O
while	while	IN	B-SBAR	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
hospital	hospital	NN	I-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
dictated	dictated	JJ	I-NP	O
summary	summary	NN	I-NP	O
ENTERED	ENTERED	NNP	I-NP	O
BY	BY	NNP	I-NP	O
:	:	:	O	O
TIMMER	TIMMER	NN	B-NP	O
,	,	,	O	O
ROLF	ROLF	NNP	B-NP	O
P.	P.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
AJ86	AJ86	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
11/17/07	11/17/07	CD	I-NP	O
@	@	SYM	B-NP	O
02	02	CD	I-NP	O
******	******	SYM	I-NP	O
END	END	NN	I-NP	O
OF	OF	IN	B-PP	O
DISCHARGE	DISCHARGE	NN	B-NP	O
ORDERS	ORDERS	NNS	I-NP	O
******	******	SYM	B-NP	O

